BigHat CEO says protein design possible in 20 minutes
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Peyton Greenside is CEO of BigHat Biosciences, which uses machine‑learning to design antibody therapies.
- Peyton Greenside says she can generate a protein design in about 20 minutes, far faster than the six‑hour demos often shown.
- BigHat Biosciences acknowledges that after design, downstream testing and manufacturing still require extensive time and capital.
- Peyton Greenside warns that the real bottleneck in drug development is experimental validation and production, not computational design.
Why it matters: Pharma firms and investors stand to gain from realistic expectations about AI’s role, while startups that overpromise rapid drug creation risk losing credibility and funding.
Ask SkimNews
